Navigation Links
Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
Date:6/30/2010

PITTSBURGH, June 30 /PRNewswire/ -- Precision Therapeutics, a life-science company known for their expertise in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, continues to gain ground in novel genomic testing and bioinformatics research.  

Precision Therapeutics has recently recruited key scientific research experts, biostatisticians and medical specialists to support their development efforts. "I think Precision is addressing a very important clinical question, using a unique scientific approach that holds high potential to realizing personalized medicine," states Shuguang Huang, Ph.D., newly appointed Director of Bioinformatics at Precision. Huang is the former Director of Discovery Biostatistics and Translational Medicine for Wyeth Research, and was previously a Senior Research Scientist for Eli Lilly and Co.

It is Precision's dedication to ongoing research and clinical trials that has attracted top-level physicians and research scientists. Chunqiao Tian, Ph.D., was also recruited to join the company as the Director of Biostatistics. "I came to Precision because I believe that individualized therapy is the future of cancer treatment, and this company plays a leading role in that field," states Dr. Tian.   Tian was an International Visiting Scholar and leading biostatistician with the Gynecologic Oncology Group (GOG), a non-profit clinical and scientific research organization in the field of gynecologic malignancies.

The clinical trials team at Precision has been augmented with the addition of Hong Ma, M.D., a medical oncologist and expert in Phase I-IV clinical trials.  Dr. Ma comes to Precision with 16 years of experience in clinical trials with a focus in oncology, medical devices and drug development.

Precision is actively developing multi-genomic predictors of patient response to cancer therapy. State-of-the-art bioinformatics combined with the company's proprietary live tissue platform provides a unique foundation and methodology for development and commercialization of these novel predictive markers for cancer therapy.  Early validation data presented at AACR 2010 shows promising results for novel multi-gene predictors currently in development.

Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. ChemoFx® has shown positive outcomes in patient survival rates while significantly lowering healthcare costs when a physician chooses a therapy deemed responsive by the marker.  

Precision Therapeutics, led by CEO Sean McDonald, has tripled its number of employees in a little over 3 years, and plans to open a second clinical laboratory in the Lawrenceville sector of Pittsburgh in July, 2010.  

For more information, please visit www.precisiontherapeutics.com or www.chemofx.com.


'/>"/>
SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stretching single molecules allows precision studies of interacting electrons
2. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
3. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
4. New statistical technique improves precision of nanotechnology data
5. Precision Stability Storage Announces Upcoming Expansion
6. NISTs LIDAR may offer peerless precision in remote measurements
7. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
8. AMDL, Inc. Signs First Customer Agreement With Precision Diagnostic Laboratory for DR-70 (FDP) Cancer Test
9. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
10. Applied Precision Introduces New Super-Resolution Imaging System Doubling Resolution of Traditional Microscopes
11. SACHEM Launches 2-D HPLC e-Learning Program : New e-Learning Program Teaches Scientists How to Better Analyze and Prove Product Purity Through Greater Sensitivity and Precision in Identification of Trace Components
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):